Rapid Diagnostic Technology for AUGIB Based on Analysis of VOCs in Exhaled Breath
Launched by BEIJING 302 HOSPITAL · Mar 10, 2025
Trial Information
Current as of April 23, 2025
Not yet recruiting
Keywords
ClinConnect Summary
Acute upper gastrointestinal bleeding (AUGIB) is a common emergency with an annual incidence of 100-180/100,000 and mortality of 2%-15%. Endoscopy, the gold standard, is invasive and equipment-dependent, limiting its use in primary care or emergencies. Exhaled breath VOCs analysis, a non-invasive and portable method, has been applied in other diseases but not yet explored for AUGIB.
Objectives:
1. Identify characteristic VOC profiles in exhaled breath of AUGIB patients.
2. Develop a VOC-based predictive model with sensitivity and specificity ≥0.7.
3. Establish rapid diagnostic criteria to...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age ≥18 years;
- • 2. Clinical suspicion of AUGIB (e.g., hematemesis, melena);
- • 3. Fasting ≥4 hours;
- • 4. Signed informed consent.
- Exclusion Criteria:
- • 1. Severe pulmonary dysfunction or recent lung infection (within 1 week);
- • 2. Cardiac/renal failure or disseminated intravascular coagulation;
- • 3. Contraindications to endoscopy;
- • 4. High-risk conditions (e.g., massive ascites);
- • 5. Alcohol consumption within 24 hours;
- • 6. Pregnancy.
About Beijing 302 Hospital
Beijing 302 Hospital is a leading medical institution in China, renowned for its advanced clinical research and comprehensive healthcare services. As a sponsor of clinical trials, the hospital is committed to advancing medical knowledge and improving patient outcomes through rigorous scientific inquiry and innovation. With a multidisciplinary team of experienced researchers and healthcare professionals, Beijing 302 Hospital focuses on a wide range of therapeutic areas, employing state-of-the-art facilities and methodologies to ensure the highest standards of trial integrity and patient safety. The hospital's dedication to ethical practices and collaboration fosters an environment conducive to groundbreaking research and the development of new treatment modalities.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported